Table 1.

Analysis of cGMP TCMC-trastuzumab following labeling with ²¹²Pb.

Months	% Efficiency	% Free Chelate	Specific Activity (mCi/mg)	% Purity (SE-HPLC)
0	92.2	0.6	3.2	100.0
3	92.2	0.2	3.3	ND
6	94.8	0.1	2.8	100.0
12	99.6	0.4	3.2	100.0
18	99.6	0.4	4.6	100.0
24	98.0	0.4	4.0	91.5
36	98.8	0.4	5.1	100.0
48	93.5	0.6	3.1	100.0
60	98.2	1.6	6.0	90.2